Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2

被引：0
|
作者：
Kortuem, M. [1 ]
Trudel, S. [2 ]
Cohen, A. D. [3 ]
Richardson, P. G. [4 ]
Lonial, S. [5 ]
Opalinska, J. B. [6 ]
Gupta, I [6 ]
Byrne, J. [6 ]
Zhi, E. [6 ]
Baron, J. [6 ]
Morgan, L. [6 ]
Voorhees, P. M. [7 ]
Popat, R. [8 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin 2, Wurzburg, Germany
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] GlaxoSmithKline, Upper Providence, PA USA
[7] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[8] NHS Fdn Trust, Univ Coll London Hosp, London, England
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
203
引用
收藏
页码：97 / 98
页数：2
相关论文
共 50 条
  • [41] Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
    Callander, Natalie S.
    Richardson, Paul G.
    Hus, Marek
    Ribrag, Vincent
    Lopez, Joaquin Martinez
    Kim, Kihyun
    Lee, Jae Hoon
    Dimopoulos, Meletis
    Schjesvold, Fredrik
    Facon, Thierry
    Jo, Jae-Cheol
    Min, Chang-Ki
    Mielnik, Michal
    Cheng, Shinta
    Smith, L. Mary
    Breitbach, Caroline J.
    Brawley, Chris
    Sembhi, Harjeet
    LaMacchia, John
    Hakim, Shawn
    Kremer, Brandon E.
    Grosicki, Sebastian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S507 - S508
  • [42] Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (GSK2857916; belamaf; BLENREP)
    Kortuem, M.
    Terpos, E.
    Badros, A.
    Popat, R.
    Rodriguez-Otero, P.
    Farooq, A.
    Jeng, B.
    Esposti, Degli S.
    Lewis, E.
    Gupta, I
    Opalinska, J.
    Palumbo, A.
    Trudel, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 204
  • [43] A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)
    Weisel, Katja
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Gabor, Mikala
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Boyle, Julia
    Opalinska, Joanna
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S505
  • [44] Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
    Hungria, Vania
    Weisel, Katja
    Currie, Brooke
    Perera, Sue
    Sule, Neal
    He, Wei
    Davy, Katherine
    McKeown, Astrid
    Sapra, Sandhya
    Nelsen, Linda
    Li, Mary
    Barale, Sophie
    Boyle, Julia
    McPoyle, Kaytlyn
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S505
  • [45] A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.
    Weisel, Katja
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Boyle, Julia
    Opalinska, Joanna
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
    Weisel, Katja
    Hopkins, Thomas G.
    Fecteau, Doug
    Bao, Weichao
    Quigley, Corinne
    Jewell, Roxanne C.
    Nichols, Maureen
    Opalinska, Joanna
    BLOOD, 2019, 134
  • [47] Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim
    Jakubowiak, Andrzej
    BLOOD, 2020, 136
  • [48] DREAMM-3: a phase III, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Weisel, K.
    Dimopoulos, M. A.
    Hungria, V. T. M.
    Radino, A.
    Delimpasi, S.
    Mikala, G.
    Masszi, T.
    Li, J.
    Capra, M.
    Matsumoto, M.
    Sule, N.
    Li, M.
    McKeown, A.
    He, W.
    Bright, S.
    Currie, B.
    Boyle, J.
    Opalinska, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 233 - 234
  • [49] Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
    Popat, Rakesh
    Augustson, Bradley
    Gironella, Mercedes
    Lee, Cindy
    Cannell, Paul
    Patel, Nashita
    Kasinathan, Ravi S.
    Rogers, Rachel
    Shaikh, Mehreen
    Curry, Amy
    Carreno, Fernando
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Quach, Hang
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [50] Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
    Dimopoulos, Meletios Athanasios
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Perera, Sue
    Boyle, Julia
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Weisel, Katja
    LANCET HAEMATOLOGY, 2023, 10 (10): : E801 - E812
12345